ALSUntangled advises against off-label propofol use in ALS
Original source
Propofol (opens in a new tab)ALSUntangled reviewed reports and available patient data on propofol in amyotrophic lateral sclerosis (ALS). Six patients reported subjective benefits online, but these were not confirmed with validated outcome measures. The review found objective improvement in only one of 235 patients and advised against off-label propofol use for ALS.
Why this matters
This applies to people with ALS considering propofol outside its approved uses. The review says any possible benefit remains uncertain, while the drug’s risks and costs do not appear justified for off-label treatment. Propofol may still be used for procedures or surgery, but this review does not show that it treats ALS.
Limitations and context
This is an independent expert review, not a clinical trial. The patient reports came from an online discussion, and the 235-patient figure combined cases from several sources. The review could not conclusively rule out a very brief benefit in rare patients, and its conclusions do not establish whether propofol affects ALS disease progression.